AptarGroup, Inc.
NYSE:ATR · New York Stock Exchange
+$0.66 today
Vol 0.37M · Avg 0.51M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
14.7%
avg 14.4%
ROIC
9.2%
avg 8.8%
ROA
7.5%
avg 6.8%
Analysis
ROE is currently the strongest return metric at 14.7% versus its period average of 14.4%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Stephan Tanda | President, Chief Executive Officer & Executive Director | $1.75M | — | 61 | $254,267.00 | 0.40% |
Gael Touya | President of Aptar Pharma | $1.62M | — | 56 | $37,017.00 | 0.06% |
Hedi Tlili | President of Aptar Closures | $1.10M | — | 51 | $24,233.00 | 0.04% |
Vanessa Kanu | Executive Vice President & Chief Financial Officer | $1.06M | — | 48 | $24,646.00 | 0.04% |
Xiangwei Gong | Executive VP of Strategic Group Development & President of Aptar Asia | $1.06M | — | 56 | $10,774.00 | 0.02% |
Marc Prieur | President of Aptar Beauty | $964,014.00 | — | 60 | $19,323.00 | 0.03% |
Irene Hudson | Executive Vice President, Chief Legal Officer & Corporate Secretary | — | — | 49 | $0.00 | <0.01% |
Mary Skafidas | Senior Vice President of Investor Relations & Communications | — | — | — | — | — |
Daniel Richard Ackerman | Senior VP, Principal Accounting Officer & Chief Accounting Officer | — | — | 53 | $32,779.00 | 0.05% |
Alex Theodorakis | Head of Pharma Prescription | — | — | — | — | — |
Shiela Pallerne Vinczeller | Chief Human Resources Officer | — | — | 62 | $27,291.00 | 0.04% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
14
$4.71M
Net Sentiment
$4.71M
Net selling
Most Active
Vinczeller Shiela
4 transactions
1–10 of 14
Analysis
Insiders reported 0 buys worth $0.00 and 14 sells worth $4.71M over the last 12 months. That adds up to net selling of $4.71M. Vinczeller Shiela was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +9.1% | +6.6% (13yr)2 analysts |
| Revenue | N/A | N/A | -0.2% | +5.1% (13yr)3 analysts |
| Net Income | N/A | N/A | +7.0% | +6.9% (13yr)3 analysts |
| EBIT | N/A | N/A | +7.8% | +4.2% (13yr)3 analysts |
Analysis
Recent growth has been strongest in EPS at +9.1% over three years. Forward estimates point to Net Income at +6.9% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Globus Medical, Inc.
NYSE:GMED
$10.25B
Molina Healthcare, Inc.
NYSE:MOH
$10.23B
Masimo Corporation
NASDAQ:MASI
$9.42B
Henry Schein, Inc.
NASDAQ:HSIC
$9.10B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.17B
Repligen Corporation
NASDAQ:RGEN
$7.34B
Avantor, Inc.
NYSE:AVTR
$6.52B
Grifols, S.A.
NASDAQ:GRFS
$6.33B
Teleflex Incorporated
NYSE:TFX
$5.50B
Stevanato Group S.p.A.
NYSE:STVN
$4.74B
Who manages ATR?
AptarGroup, Inc. (ATR) lists 11 active executives. The top listed executive is Gael Touya, President of Aptar Pharma.
Are ATR insiders buying or selling?
Recent insider activity shows net selling of $4.73M.
Explore More
Continue the stock analysis
Jump to another research area for this company.